

## Be Ready For The Biosimilar Boom

Only 11 biosimilar drugs have been approved to date, five from 2017. Recent FDA guidance opens the door to more and quicker approvals. With strong demand for less expensive drug options the biosimilar market is bound to heat up.

**Get expert analysis and practical guidance for biosimilar drugs below:**

**EXPERT ANALYSIS: FDA Biosimilars Plan Draws From Experience With Generics**

**BIOSIMILARS ENTER THE COURTS:  
How will patent infringement settlements be tested for validity under antitrust laws?**

**LEXIS PRACTICE ADVISOR:  
Biosimilars and the Biologics Price Competition and Innovation Act**



### **The Fight For The New Market**

The debate between drugmakers over cheaper pills has been brewing for years. In 1984, a landmark federal law cleared the way for the market for simple generic pills to flourish, making copycats of expensive brand-name drugs available for pennies on the dollar and saving consumers billions. In 2010, a new law was passed that sought to do the same for complex biotechnology drugs. [Brand-Name Drugmakers Turn on Each Other in Fight for New Market, Broward Daily Business Review, September 27, 2018.](#)